Lampen P, Neumeyer J L, Baldessarini R J
Section of Medicinal Chemistry, College of Pharmacy and Allied Health Professions, Northeastern University, Boston, MA 02115.
J Chromatogr. 1988 Apr 29;426(2):283-94. doi: 10.1016/s0378-4347(00)81956-8.
The dopamine receptor agonist R(-)N-n-propylnorapomorphine (NPA) and its proposed pro-drug R(-)10,11-methylenedioxy-N-n-propylnoraporphine (MDO-NPA) were isolated simultaneously from monkey plasma using a solid-phase extraction procedure. R(-)Apomorphine (APO) and R(-)10,11-methylenedioxyaporphine (MDO-APO) were added as internal standards, and separation and quantification were by high-performance liquid chromatography with electrochemical or ultraviolet detection of the free catechol and MDO compounds, respectively. The detection limits for NPA and MDO-NPA in plasma were 0.5 and 10 ng/ml and the coefficient of variation (S.D./mean) within assays and between days of assays for both drugs was 5.6% or less. Quantification of plasma levels of NPA and MDO-NPA was possible at ranges of 2-1000 and 40-5000 ng/ml, respectively, including concentrations found after intravenous administration of these agents.
采用固相萃取法从猴血浆中同时分离出多巴胺受体激动剂R(-)-N-正丙基去甲阿扑吗啡（NPA）及其拟前体药物R(-)-10,11-亚甲二氧基-N-正丙基去甲阿朴啡（MDO-NPA）。加入R(-)-阿扑吗啡（APO）和R(-)-10,11-亚甲二氧基阿朴啡（MDO-APO）作为内标，分别通过高效液相色谱法对游离儿茶酚和MDO化合物进行电化学检测或紫外检测来进行分离和定量。血浆中NPA和MDO-NPA的检测限分别为0.5和10 ng/ml，两种药物在分析内和分析日之间的变异系数（标准差/平均值）均为5.6%或更低。分别在2-1000 ng/ml和40-5000 ng/ml范围内可对血浆中NPA和MDO-NPA水平进行定量，包括静脉注射这些药物后测得的浓度。
